Massively Parallel Sequencing/Multiplex Ligation-Dependent Probe Amplification (MLPA)
If a familial sequence variant has been previously identified, targeted sequencing for that variant may be appropriate; refer to the Laboratory Test Directory for additional information.
Pathogenic variants in the SHOX gene result in a spectrum of disorders due to haploinsufficiency of the SHOX gene. Clinical features often include short stature, mesomelia (shortening of the lower portion of arm and leg), and abnormal alignment of the radius, ulna, and carpal bones at the wrist (Madelung deformity). Variable expressivity results in some individuals only affected with isolated short stature (ISS), whereas others have short stature and additional findings resulting in syndrome disorders (eg, Leri-Weill dyschondrosteosis [LWD] or Langer mesomelic dysplasia [LMD]).
Disease Overview
Epidemiology
The prevalence for SHOX deficiency disorders is at least 1/1,000
Associated Conditions
Genetics
Inheritance
- Homologous SHOX genes are located on the X chromosome and Y chromosome and follow autosomal inheritance instead of sex-linked inheritance.
- A SHOX pathogenic variant causing a SHOX deficiency disorder can be located on either of the X chromosomes in a female or on either the X or Y chromosome in a male.
- Pseudoautosomal dominant for LWD and ISS; haploinsufficiency caused by only one functional/expressed copy of SHOX gene
- Pseudoautosomal recessive for LMD; complete loss of SHOX function/expression due to biallelic inactivation
Penetrance
High, with variable expressivity and an increased female:male ratio
Etiology
- Deletions account for 80-90% of pathogenic variants
- Range from single exon deletions to >2.5 Mb or larger
- Intragenic deletions and deletions involving enhancer elements are reported
- Sequence variants account for 10-20% of pathogenic variants
Test Interpretation
Methodology
This test is performed using the following sequence of steps:
- Selected genomic regions, primarily coding exons and exon-intron boundaries, from the targeted genes are isolated from extracted genomic DNA using a probe-based hybrid capture enrichment workflow.
- Enriched DNA is sequenced by massively parallel sequencing (MPS; also known as NGS) followed by paired-end read alignment and variant calling using a custom bioinformatics pipeline.
- Sanger sequencing is performed as necessary to fill in regions of low coverage and in certain situations, to confirm variant calls.
- Multiplex ligation-dependent probe amplification (MLPA) is performed to call exon-level deletions and duplications.
Clinical Sensitivity
- At least 90% for SHOX deficiency disorders
- About 10% of individuals with LWD do not have a demonstrable SHOX pathogenic variant
Analytic Sensitivity/Specificity
For massively parallel sequencing:
Variant Class | Analytic Sensitivity (PPA) Estimatea (%) and 95% Credibility Region (%) |
Analytic Specificity (NPA) (%) |
---|---|---|
SNVs |
>99 (96.9-99.4) |
>99.9 |
Deletions 1-10 bpb |
93.8 (84.3-98.2) |
>99.9 |
Insertions 1-10 bpb |
94.8 (86.8-98.5) |
>99.9 |
aGenes included on this test are a subset of a larger methods-based validation from which the PPA values are derived. bVariants greater than 10 bp may be detected, but the analytical sensitivity may be reduced. bp, base pairs; NPA, negative percent agreement; PPA, positive percent agreement; SNVs, single nucleotide variants |
MLPA
>99%
Results
Result | Variant(s) Detected | Clinical Significance |
---|---|---|
Positive |
One pathogenic SHOX variant detected |
Confirms a diagnosis of LWD or ISS |
Two pathogenic SHOX variants detected |
Confirms diagnosis of LMD if located on opposite chromosomes |
|
Negative |
No pathogenic SHOX variants detected |
Decreases likelihood of, but does not exclude, a diagnosis of a SHOX deficiency disorder |
Inconclusive |
Variant of uncertain clinical significance detected |
Diagnosis of a SHOX deficiency disorder can neither be confirmed nor excluded |
Limitations
- A negative result does not exclude a diagnosis of a SHOX deficiency disorder.
- Diagnostic errors can occur due to rare sequence variations.
- Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation.
- SHOX (NM_006883) exon 6, also known as exon 6b, is not sequenced due to technical limitations of the assay.
- The following will not be evaluated:
- Variants outside the coding regions and intron-exon boundaries of targeted gene(s)
- Regulatory region and deep intronic variants
- Breakpoints of large deletions/duplications
- The following may not be detected:
- Deletions/duplications/insertions of any size by massively parallel sequencing
- Noncoding transcripts
- Low-level somatic variants
- Certain other variants due to technical limitations in the presence of pseudogenes and repetitive/homologous regions
- MLPA results suggestive of aneuploidy will require further analyses by other methods (eg, chromosome analysis/karyotype, microarray, etc.) for confirmation.
References
-
GeneReviews - SHOX Deficiency Disorders
Binder G, Rappold GA. SHOX deficiency disorders. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews. University of Washington, Seattle. Last update Jun 2018; accessed Dec 2021.
-
27355317
Marchini A, Ogata T, Rappold GA. A track record on SHOX: from basic research to complex models and therapy. Endocr Rev. 2016;37(4):417-448.
-
Online Mendelian Inheritance in Man
Online Mendelian inheritance in man. John Hopkins University. Updated Dec 2021; accessed Dec 2021.
Use to detect pathogenic variants in the SHOX gene which cause SHOX deficiency disorders (eg, ISS, LWD, or LMD)